Abuse of nutmeg (Myristica fragrans Houtt.): Studies on the metabolism and the toxicologic detection of its ingredients elemicin, myristicin, and safrole in rat and human urine using gas chromatography/mass spectrometry

Therapeutic Drug Monitoring

Volumn 28, Issue 4, 2006, Pages 568-575

  Beyer, Jochen ^a   Ehlers, Dorothea ^b   Maurer, Hans H ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b NONE   (Germany)

Author keywords

Detection; Gas chromatography mass spectrometry; Herbal drug; Metabolism; Nutmeg

Indexed keywords

AMPHETAMINE DERIVATIVE; ELEMICIN; MYRISTICIN; SAFROLE;

ACETYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DRUG ABUSE; GAS CHROMATOGRAPHY; HUMAN; HYDROXYLATION; LIQUID LIQUID EXTRACTION; MALE; MASS SPECTROMETRY; METABOLITE; METHYLATION; MICROWAVE RADIATION; NONHUMAN; NUTMEG; PRIORITY JOURNAL; RAT; URINALYSIS;

ANIMALS; BENZYL COMPOUNDS; DIOXOLANES; DRUG MONITORING; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MOLECULAR STRUCTURE; MYRISTICA FRAGRANS; PYROGALLOL; RATS; RATS, WISTAR; REPRODUCIBILITY OF RESULTS; SAFROLE; SEEDS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SUBSTANCE ABUSE DETECTION; SUBSTANCE-RELATED DISORDERS; TIME FACTORS;

EID: 33746309901     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200608000-00013     Document Type: Article

References (36)

1. Farnsworth NR. Hallucinogenic plants. Science. 1968;162:1086-1092.
2. Beck TA, Marty H. Die Nervenkekse der Hildgard von Bingenkeine harmlose Nascherei. Schweiz Med Forum. 2001;51/52:1287-1288.
3. Lavy G. Nutmeg intoxication in pregnancy. A case report. J Reprod Med. 1987;32:63-64.
4. Servan J, Chochon F, Duclos H. Hallucinations after voluntary ingestion of nutmeg: an unrecognized drug abuse. Rev Neurol (Paris). 1998;154:708.
5. Forrester MB. Nutmeg intoxication in Texas, 1998-2004. Hum Exp Toxicol. 2005;24:563-566.
6. Demetriades AK, Wallman PD, McGuiness A, et al. Low cost, high risk: accidental nutmeg intoxication. Emerg Med J. 2005;22:223-225.
7. Abernethy MK, Becker LB. Acute nutmeg intoxication. Am J Emerg Med. 1992;10:429-430.
8. Sangalli BC, Chiang W. Toxicology of nutmeg abuse. J Toxicol Clin Toxicol. 2000;38:671-678.
9. Stein U, Greyer H, Hentschel H. Nutmeg (myristicin) poisoning - report on a fatal case and a series of cases recorded by a poison information centre. Forensic Sci Int. 2001;118:87-90.
10. McKenna A, Nordt SP, Ryan J. Acute nutmeg poisoning. Eur J Emerg Med. 2004;11:240-241.
11. 2 extraction-comparison with steam distilled oils-comparison of East Indian, West Indian and Papuanan oils. Int J Food Sci Technol. 1998;33:215-223.
12. Shulgin AT. Possible implication of myristicin as a psychotropic substance. Nature. 1966;210:380-384.
13. Shulgin AT. 3-Methoxy-4,5-methylenedioxy amphetamine, a new psychotomimetic agent. Nature. 1964;201:1120-1121.
14. Braun U, Kalbhen DA. Demonstration of the formation of psychotropic amphetamine derivatives from nutmeg components. Dtsch Med Wochenschr. 1972;97:1614-1615.
15. Braun U, Kalbhen DA. Evidence for the biogenic formation of amphetamine derivatives from components of nutmeg. Pharmacology. 1973;9:312-316.
16. Oswald EO, Fishbein L, Corbett BJ, et al. Identification of tertiary aminomethylenedioxypropiophenones as urinary metabolites of safrole in the rat and guinea pig. Biochim Biophys Acta. 1971;230:237-247.
17. Oswald EO, Fishbein L, Corbett BJ, et al. Urinary excretion of tertiary amino methoxy methylenedioxy propiophenones as metabolites of myristicin in the rat and guinea pig. Biochim Biophys Acta. 1971;244:322-328.
18. Solheim E, Scheline RR. Metabolism of alkenebenzene derivatives in the rat. I. p-Methoxyallylbenzene (Estragole) and p-methoxypropenylbenzene (Anethole). Xenobiotica. 1973;3:493-510.
19. Maurer HH. Position of chromatographic techniques in screening for detection of drugs or poisons in clinical and forensic toxicology and/or doping control [review]. Clin Chem Lab Med. 2004;42:1310-1324.
20. Ewald AH, Fritschi G, Bork WR, et al. Designer drugs 2,5-dimethoxy-4- bromoamphetamine (DOB) and 2,5-dimethoxy-4-bromomethamphetamine (MDOB): studies on their metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. J Mass Spectrom. 2006;41:487-498.
21. Ewald AH, Peters FT, Weise M, et al. Studies on the metabolism and toxicological detection of the designer drug 4-methylthioamphetamine (4-MTA) in human urine using gas chromatography-mass spectrometry. J Chromatogr B: Anal Technol Biomed Life Sci. 2005;824:123-131.
22. Theobald DS, Staack RF, Puetz M, et al. New designer drug 2,5-dimethoxy-4-ethylthio-beta-phenethylamine (2C-T-2): studies on its metabolism and toxicological detection in rat urine using gas chromatography/mass spectrometry. J Mass Spectrom. 2005;40:1157-1172.
23. Theobald DS, Fehn S, Maurer HH. New designer drug 2,5-dimethoxy-4- propylthiophenethylamine (2C-T-7): studies on its metabolism and toxicological detection in rat urine using gas chromatography/mass spectrometry. J Mass Spectrom. 2005;40:105-116.
24. Staack RF, Maurer HH. New designer drug 1-(3,4-methylenedioxybenzyl) piperazine (MDBP): studies on its metabolism and toxicological detection in rat urine using gas chromatography/mass spectrometry. J Mass Spectrom. 2004;39:255-261.
25. Maurer HH. On the metabolism and the toxicological analysis of methylenedioxyphenylalkylamine designer drugs by gas chromatography-mass spectrometry. Ther Drug Monit. 1996;18:465-470.
26. Ensslin HK, Kovar KA, Maurer HH. Toxicological detection of the designer drug 3,4- methylenedioxyethylamphetamine (MDE, "Eve") and its metabolites in urine by gas chromatography-mass spectrometry and fluorescence polarization immunoassay. J Chromatogr B Biomed Sci Appl. 1996;683:189-197.
27. McKay AF, Ott WL, Taylor GW, et al. Diazohydrocarbons. Can J Res. 1950;28:683-688.
28. Maurer HH. Toxicological analysis of drugs and poisons by GC-MS [review]. Spectrosc Eur. 1994;6:21-23.
29. Pfleger K, Maurer HH, Weber A. Mass Spectral Library of Drugs, Poisons, Pesticides, Pollutants and their Metabolites. 4th ed. Palo Alto, CA: Agilent Technologies; 2006. In preparation.
30. McLafferty FW, Turecek F. Interpretation of Mass Spectra. 4th ed. Mill Valley, CA: University Science Books; 1993.
31. Smith RM, Busch KL. Understanding Mass Spectra - A Basic Approach. New York, NY: Wiley; 1999.
32. Maurer HH. Screening procedures for simultaneous detection of several drug classes used in the high throughput toxicological analysis and doping control [review]. Comb Chem High Throughput Screen. 2000;3:461-474.
33. Bickeboeller-Friedrich J, Maurer HH. Screening for detection of new antidepressants, neuroleptics, hypnotics, and their metabolites in urine by GC-MS developed using rat liver microsomes. Ther Drug Monit. 2001;23:61-70.
34. Maurer HH, Bickeboeller-Friedrich J. Screening procedure for detection of antidepressants of the selective serotonin reuptake inhibitor type and their metabolites in urine as part of a modified systematic toxicological analysis procedure using gas chromatography-mass spectrometry. J Anal Toxicol. 2000;24:340-347.
35. Kovats E. Gaschromatographische Charakterisierung organischer Verbindungen. Teil 1. Retentionsindices aliphatischer Halogenide, Alkohole, Aldehyde und Ketone. Helv Chim Acta. 1958;41:1915-1932.
36. de-Zeeuw RA, Franke JP, Maurer HH, et al. Gas Chromatographic Retention Indices of Toxicologically Relevant Substances and their Metabolites (Report of the DFG Commission for Clinical Toxicological Analysis, Special Issue of the TIAFT Bulletin). 3rd ed. Weinheim, New York, Basle: VCH publishers; 1992.